The availability of robust classification algorithms for the identification of high risk individuals
with resectable disease is critical to improving early detection strategies and ultimately …

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with five-year
survival rates around 10%. The only curative option remains complete surgical resection, but …

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and lethal
cancers, with a 5-year survival rate of less than 5%. In fact, complete surgical resection …

The incidence of pancreatic ductal adenocarcinoma (PDAC) is increasing. The projection
that it will surpass breast cancer to become the second-leading cause of cancer-related …

Our study aimed to identify a urinary metabolite panel for the detection/diagnosis of
pancreatic ductal adenocarcinoma (PDAC). PDAC continues to have poor survival …

Background & Objectives Pancreatic ductal adenocarcinoma remains an extremely
malignant tumor having a poor prognosis. The 5-year survival rate of PDAC is related to its …

Background We applied a training and testing approach to develop and validate a plasma
metabolite panel for the detection of early-stage pancreatic ductal adenocarcinoma (PDAC) …

Background Early detection of pancreatic ductal adenocarcinoma (PDAC) may improve the
prognosis of patients. This study was to identify metabolic features of PDAC and to discover …

Simple Summary A highly desirable approach to diagnose a human disease quickly and
easily is to identify a chemical, protein, or antibody in a biofluid like blood or urine that is …

Pancreatic cancer (PC) is an aggressive disease with high mortality rates, however, there is
no blood test for early detection and diagnosis of this disease. Several research groups …